Immune Response launches mid stage trial of new MS treatment
11th October 2006
By Victoria Harrison
The Immune Response Corporation has launched a phase II trial to assess the potential of NeuroVax to treat patients with multiple sclerosis.
NeuroVax is an investigational T-cell receptor (TCR) peptide vaccine.
The company has secured two new partners for the launch of its phase II trial of Neurovax. NeuroRx Research and Accelsiors CRO & Consultancy Services have been contracted to oversee the study.
The company said that it expects patient enrollment of the trial to begin before the end of the year. The trial will examine the effectiveness and safety of NeuroVax versus placebo.
The treatment could be a breakthrough for MS sufferers as side effects have so far been limited and so NeuroVax could prove easy for patients to tolerate compared to existing MS therapies.
"This treatment may have the ability to alter how the immune system fights MS," said Krzysztof Selmaj, Department of Neurology, Medical University of Lodz, Poland.
Previous results have showed that NeuroVax was able to restore normal levels of FOXP3+ Treg cells in patients. These Treg or regulatory T-cells appear to help control levels of pathogenic T-cells in MS patients.
MS is an autoimmune disease in which the immune system mistakenly attacks normal tissues of the central nervous system. The disease is caused by activation of a specific subset of the patient's own white blood cells or pathogenic T-cells.
By restoring healthy regulatory T-cell function, NeuroVax may offer a new mechanism to control pathogenic T-cell activity and limit or prevent nerve tissue damage in MS patients.
http://www.pharmaceutical-business-review.com/article_news.asp?guid=05529B81-C95C-47F4-89C6-0CEB7D450086
RELATED NEWS
©2006 Business Review Ltd
Return to PBR Online
Click here to find out more!
http://www.pharmaceutical-business-review.com/article_news.asp?guid=05529B81-C95C-47F4-89C6-0CEB7D450086
By Victoria Harrison
The Immune Response Corporation has launched a phase II trial to assess the potential of NeuroVax to treat patients with multiple sclerosis.
NeuroVax is an investigational T-cell receptor (TCR) peptide vaccine.
The company has secured two new partners for the launch of its phase II trial of Neurovax. NeuroRx Research and Accelsiors CRO & Consultancy Services have been contracted to oversee the study.
The company said that it expects patient enrollment of the trial to begin before the end of the year. The trial will examine the effectiveness and safety of NeuroVax versus placebo.
The treatment could be a breakthrough for MS sufferers as side effects have so far been limited and so NeuroVax could prove easy for patients to tolerate compared to existing MS therapies.
"This treatment may have the ability to alter how the immune system fights MS," said Krzysztof Selmaj, Department of Neurology, Medical University of Lodz, Poland.
Previous results have showed that NeuroVax was able to restore normal levels of FOXP3+ Treg cells in patients. These Treg or regulatory T-cells appear to help control levels of pathogenic T-cells in MS patients.
MS is an autoimmune disease in which the immune system mistakenly attacks normal tissues of the central nervous system. The disease is caused by activation of a specific subset of the patient's own white blood cells or pathogenic T-cells.
By restoring healthy regulatory T-cell function, NeuroVax may offer a new mechanism to control pathogenic T-cell activity and limit or prevent nerve tissue damage in MS patients.
http://www.pharmaceutical-business-review.com/article_news.asp?guid=05529B81-C95C-47F4-89C6-0CEB7D450086
RELATED NEWS
COMPANIES MENTIONED
©2006 Business Review Ltd
Return to PBR Online
Click here to find out more!
http://www.pharmaceutical-business-review.com/article_news.asp?guid=05529B81-C95C-47F4-89C6-0CEB7D450086
posted by Bill at 10:25 PM
0 Comments:
Post a Comment
<< Home